7 completed, 1 recruiting, 1 unknown. 4 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Unknown 1 |
Follow eflapegrastim: new trials by email Literature Review of eflapegrastim trials Research Report on eflapegrastim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy Eflapegrastim - Breast Neoplasms | Phase 4 | Unknown | Eunseong Medical Foundation Good GANG-AN HOSPITAL | 100 | 2023-11-07 | 2024-02-23 |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy Eflapegrastim, Chemotherapy - Solid Tumors, Lymphoma | Phase 2 | Recruiting | Spectrum Pharmaceuticals, Inc | 40 | 2021-05-20 | 2026-10-28 |
| Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer Eflapegrastim, Docetaxel, Cyclophosphamide - Neutropenia, Breast Cancer | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 59 | 2020-03-11 | 2024-09-19 |
| Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy SPI-2012 - Breast Cancer, Pharmacokinetics | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 26 | 2017-05-11 | 2020-11-13 |
| SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia, Breast Cancer | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 237 | 2017-05-10 | 2022-03-02 |
| SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia, Breast Cancer | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 406 | 2016-01-19 | 2022-03-02 |
| Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia | Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 148 | 2013-03-25 | 2022-04-15 |
| Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects HM10460A or placebo or Neulasta - Healthy | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 84 | 2009-11-01 | 2014-02-07 |
| Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects HM10460A 5μg/kg, HM10460A 15μg/kg, HM10460A 45μg/kg - Healthy | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 40 | 2009-10-01 | 2014-02-07 |
Breast Neoplasms (5) · Neutropenia (4) · Lymphoma (1)
Spectrum Pharmaceuticals, Inc (6) · Hanmi Pharmaceutical Company Limited (2) · Eunseong Medical Foundation Good GANG-AN HOSPITAL (1)
United States (7) · South Korea (4) · Canada (2) · Hungary (2) · Poland (2) · Australia (1) · Georgia (1) · India (1) · Israel (1)
Chang Wan Jeon, Ph.D (1) · Shanta Chawla, MD (1)
2016 (1)